Dogwood Therapeutics, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Stockholders' Equity (Details)

Stockholders' Equity (Details)					1 Months Ended	9 Months Ended
Stockholders' Equity (Details)	Sep. 29, 2025 $ / shares shares	Apr. 07, 2025 shares	Mar. 12, 2025 USD ($) $ / shares shares	Oct. 17, 2024	Sep. 30, 2025 USD ($) $ / shares shares	Sep. 30, 2025 USD ($) $ / shares shares	Sep. 30, 2024 USD ($)	Jun. 30, 2025 shares	Mar. 31, 2025 USD ($) shares	Dec. 31, 2024 $ / shares shares	Oct. 31, 2024 shares	Oct. 07, 2024 $ / shares	Dec. 31, 2023 $ / shares shares	Dec. 16, 2020 $ / shares shares
Stockholders' Equity
Preferred stock authorized (in shares)											2,000,000		2,000,000
Preferred stock, par value (in dollars per share) \| $ / shares													$ 0.0001
Temporary equity, shares authorized (in shares)					2,104	2,104				2,270
Temporary equity, shares issued (in shares)					2,103.1494	2,103.1494				2,213.8044
Temporary equity, shares outstanding (in shares)					2,103.1494	2,103.1494		2,269.1494	2,213.8044	2,213.8044
Dividends payable \| $									$ 1,770,767
Waiver of Series A Non-voting Convertible Preferred Stock \| $					$ 5,500,000
Waiver of cash settlement and related repurchase rights for series A preferred stock					166
Common stock authorized (in shares)					43,000,000	43,000,000				43,000,000				43,000,000
Common stock, par value (in dollars per share) \| $ / shares					$ 0.0001	$ 0.0001				$ 0.0001				$ 0.0001
Net proceeds from issuance of common stock \| $						$ 4,252,245	$ 1,382,170
License for SP16 Development \| Serpin License Agreement
Stockholders' Equity
Total Consideration Paid						12,030,667
Common Stock \| License for SP16 Development \| Serpin License Agreement
Stockholders' Equity
Total Consideration Paid						2,108,828
Series A Non-Voting Convertible Preferred Stock
Stockholders' Equity
Temporary equity, shares authorized (in shares)					2,270	2,270				2,270	2,270
Temporary equity, shares issued (in shares)					2,269.1494	2,269.1494				2,213.8044
Temporary equity, shares outstanding (in shares)					2,269.1494	2,269.1494
Percentage of original shares remaining issued and outstanding						30.00%
Shares automatically converted						10,000
Preferred Stock
Stockholders' Equity
Preferred stock dividend rate percentage						5.00%
Preferred stock dividend payment period		180 days				180 days
PIK dividend, shares		55.345
Series A1 Convertible Preferred Stock
Stockholders' Equity
Preferred stock authorized (in shares)					285	285			285	0
Preferred stock, par value (in dollars per share) \| $ / shares			$ 0.0001
Preferred stock issued (in shares)					284.2638	284.2638				0
Preferred stock outstanding (in shares)					284.2638	284.2638				0
Minimum percentage of Preferred stock issued and outstanding						30.00%
No. of share issued during conversion			10,000		10,000	10,000
Series A2 Convertible Preferred stock
Stockholders' Equity
Preferred stock authorized (in shares)					190.0572	190.0572
Preferred stock issued (in shares)										0
Preferred stock outstanding (in shares)					190.0572	190.0572
Minimum percentage of Preferred stock issued and outstanding						30.00%
No. of share issued during conversion					10,000	10,000
Series A-2 Non-Voting Convertible Preferred Stock
Stockholders' Equity
Preferred stock authorized (in shares)					190.0572	190.0572				0
Preferred stock, par value (in dollars per share) \| $ / shares					$ 0.0001	$ 0.0001				$ 0.0001
Preferred stock issued (in shares)					190.0572	190.0572				0
Preferred stock outstanding (in shares)					190.0572	190.0572				0
Series A-2 Non-Voting Convertible Preferred Stock \| License for SP16 Development \| Serpin License Agreement
Stockholders' Equity
Total Consideration Paid						9,800,839
Series A Non-Voting Convertible Preferred Stock
Stockholders' Equity
Preferred stock authorized (in shares)					166	166				0
Preferred stock, par value (in dollars per share) \| $ / shares					$ 0.0001	$ 0.0001				$ 0.0001
Preferred stock issued (in shares)					166.0000	166.0000				0
Preferred stock outstanding (in shares)					166.0000	166.0000				0
Series A Non-Voting Convertible Preferred Stock \| License for SP16 Development \| Serpin License Agreement
Stockholders' Equity
Common stock, par value (in dollars per share) \| $ / shares	$ 0.0001
Preferred Stock Excluding Series A, Series A-1 and Series A-2 Non-Voting Convertible Preferred Stock
Stockholders' Equity
Preferred stock authorized (in shares)					1,997,254	1,997,254				1,997,730
Preferred stock, par value (in dollars per share) \| $ / shares					$ 0.0001	$ 0.0001				$ 0.0001
Preferred stock issued (in shares)					0	0				0
Preferred stock outstanding (in shares)					0	0				0
Pharmagesic Holdings Inc.
Stockholders' Equity
Preferred stock, par value (in dollars per share) \| $ / shares												$ 0.0001
Number of Contingent Value Rights Issuable for each Common Share				1
Contingent value rights agreement term				7 years
Percentage of upfront payment to which holders are entitled				87.75%
Percentage ownership of outstanding rights that entitles holder to audit and enforcement				30.00%
Serpin Pharma \| License for SP16 Development \| Serpin License Agreement
Stockholders' Equity
Common stock, par value (in dollars per share) \| $ / shares	$ 0.0001
Total Consideration Paid	191,017
Serpin Pharma \| Series A-2 Non-Voting Convertible Preferred Stock \| License for SP16 Development
Stockholders' Equity
Total Consideration Paid	89.5939
Serpin Registration Rights Agreement \| Common Stock \| License for SP16 Development \| Serpin License Agreement
Stockholders' Equity
Total Consideration Paid	191,017
Serpin Registration Rights Agreement \| Series A-2 Non-Voting Convertible Preferred Stock \| License for SP16 Development \| Serpin License Agreement
Stockholders' Equity
Total Consideration Paid	89.5939
Tungsten Advisors \| Series A-2 Non-Voting Convertible Preferred Stock \| License for SP16 Development
Stockholders' Equity
Total Consideration Paid	10.8694
Registered Direct Offering
Stockholders' Equity
Shares issued			578,950
Price per share \| $ / shares			$ 8.26
Gross proceeds from issuance of shares \| $			$ 4,780,000
Net proceeds from issuance of common stock \| $			$ 4,250,000